Fremanezumab Among Latest EU Drug Hopefuls While Patients Speak Up On Pacritinib

Marketing applications for Teva’s migraine prevention CGRP inhibitor, fremanezumab, and CTI BioPharma’s myelofibrosis treatment, pacritinib, are among a number of submissions scheduled for discussion this week by the European Medicines Agency’s drug evaluation committee, the CHMP.

Headache — A new migraine prevention drug is among products up for a CHMP opinion this week. • Source: Shutterstock

Teva Pharmaceutical Industries’ migraine prevention CGRP inhibitor, fremanezumab, is one of eight products that are up for a recommendation this week on whether they should be marketed in the EU.

Also due for an opinion by the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) is